\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ is\\ remarkable\\ only\\ for\\ focal\\ back\\ pain\\,\\ there\\ was\\ no\\ cervical\\ or\\ supraclavicular\\ adenopathy\\.\\ patient\\ was\\ afebrile\\ with\\ stable\\ vital\\ signs\\.\\ ca\\-125\\ of\\ 48\\ and\\ ldh\\ of\\ 740\\ were\\ both\\ elevated\\.\ \(0\)\
\-\ chemotherapy\\ chop\\-rituximab\\ six\\ cycles\\.\\ evaluation\\ for\\ adjuvant\\ radiation\\ thereapy\\ may\\ be\\ warranted\\.\ \(0\)\
\-\ mri\\ showed\\ l3\\ compression\\ fracture\\ and\\ large\\ pelvic\\ mass\\.\\ subsequent\\ ct\\ with\\ contrast\\ revealed\\ a\\ 12\\ x18\\ heterogeneous\\ multiloculated\\ pelvic\\ mass\\ with\\ adjacent\\ collections\\ of\\ low\\ density\\ free\\ fluid\\,\\ a\\ soft\\ tissue\\ density\\ mass\\ measuring\\ 4\\ x\\ 7\\.4\\ cm\\ at\\ superior\\ pole\\ of\\ right\\ kidney\\ and\\ a\\ 7\\.6\\ x\\ 7\\.2\\ cm\\ fluid\\-filled\\ collection\\ anterior\\ to\\ ascending\\ colon\\.\\ an\\ aortocaval\\ lymphnode\\ measuring\\ 12x13\\ mm\\ and\\ additional\\ sub\\-centimeter\\ nodes\\ were\\ identified\\.\\ interval\\ ct\\ evaluation\\ after\\ second\\ cycle\\ of\\ chop\\-r\\ treatment\\ showed\\ complete\\ resolution\\ of\\ right\\ renal\\ mass\\,\\ interval\\ decrease\\ of\\ aortocaval\\ node\\,\\ and\\ interval\\ decrease\\ of\\ pelvic\\ mass\\ now\\ measuring\\ 12\\.7\\ x\\ 7\\.2\\ cm\\.\\ the\\ l3\\ compression\\ fracture\\ is\\ stable\\.\ \(0\)\
\-\ diffuse\\ large\\ b\\-cell\\ lymphoma\ \(1\)\
\-\ \\(1\\)\\ ovarian\\ carcinoma\\ \\(2\\)\\ acute\\ leukemia\\,\\ 3\\)\\ hepatocellular\\ carcinoma\\,\\ 4\\)\\ non\\ hodgkin\\â\\€\\™s\\ lymphoma\\,\\ \\(5\\)\\ pancreatic\\ tumor\ \(0\)\
\-\ this\\ 50\\-year\\-old\\ post\\ menopausal\\ woman\\ presented\\ with\\ progressive\\ back\\ pain\\ of\\ two\\ months\\ duration\\ with\\ worsening\\ after\\ a\\ fall\\ two\\ weeks\\ ago\\.\\ \\ she\\ reports\\ night\\ sweats\\ but\\ no\\ fever\\,\\ chills\\ or\\ weight\\ loss\\.\\ \\ she\\ also\\ reports\\ some\\ lower\\ extremity\\ weakness\\.\ \(0\)\
\-\ mri\\ of\\ spine\\ showed\\ l3\\ compression\\ fracture\\ and\\ incidental\\ finding\\ of\\ a\\ large\\ pelvic\\ mass\\.\\ she\\ reports\\ night\\ sweats\\ but\\ no\\ fever\\,\\ chills\\ or\\ weight\\ loss\\.\\ the\\ mass\\ was\\ worrisome\\ for\\ malignancy\\.\\ the\\ patient\\ also\\ reports\\ some\\ low\\ extremity\\ weakness\\.\\ \\ the\\ patient\\ has\\ an\\ ipi\\ \\(international\\ prognostic\\ index\\)\\ of\\ 3\\,\\ meeting\\ criteria\\ for\\ ldh\\,\\ stage\\,\\ and\\ extra\\-nodal\\ disease\\ and\\ thus\\ appears\\ to\\ have\\ a\\ poor\\ prognosis\\.\\ in\\ the\\ presence\\ of\\ a\\ pathological\\ bone\\ fracture\\ \\(l3\\)\\ the\\ patient\\â\\€\\™s\\ clinical\\ condition\\ raises\\ the\\ suspicion\\ whether\\ this\\ may\\ either\\ be\\ due\\ to\\ primary\\ or\\ secondary\\ non\\ hodgkin\\â\\€\\™s\\ lymphoma\\ of\\ the\\ bone\\.\\ in\\ a\\ retrospective\\ study\\ of\\ 23\\ patients\\ with\\ primary\\ non\\ hodgkin\\â\\€\\™s\\ lymphoma\\ of\\ the\\ bone\\ \\(plb\\)\\ it\\ was\\ found\\ that\\ most\\ were\\ due\\ to\\ diffuse\\ large\\ b\\-cell\\ lymphoma\\ and\\ three\\ cases\\ involved\\ pathologic\\ bone\\ fractures\\.\\ according\\ to\\ this\\ study\\ computed\\ tomography\\ and\\ roentgenography\\ alone\\ were\\ not\\ sufficient\\ to\\ diagnose\\ plb\\ and\\ that\\ diagnosis\\ must\\ be\\ confirmed\\ according\\ to\\ clinical\\ features\\ \\(localized\\ pain\\ and\\ tenderness\\)\\,\\ pathological\\ findings\\ and\\ immunohistochemistry\\ assay\\ \\[4\\]\\.\\ our\\ patient\\ meets\\ these\\ confirmatory\\ measures\\ and\\ given\\ the\\ fact\\ that\\ the\\ therapeutic\\ procedure\\ for\\ plb\\ mainly\\ includes\\ local\\ radiation\\ therapy\\ combined\\ with\\ chemotherapy\\,\\ our\\ patient\\ may\\ best\\ benefit\\ from\\ adjunctive\\ radiotherapy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ plb\\:\\ 0\\.055794420404851254\ \(0\)\
\-\ l3\\:\\ 0\\.04326277611689925\ \(0\)\
\-\ aortocaval\\:\\ 0\\.034271608621968576\ \(0\)\
\-\ hodgkin\\:\\ 0\\.03366462571202543\ \(0\)\
\-\ 7\\.2\\:\\ 0\\.029636113733073597\ \(0\)\
\-\ pelvic\\:\\ 0\\.029597052544854792\ \(0\)\
\-\ reports\\:\\ 0\\.02907072063999017\ \(0\)\
\-\ interval\\:\\ 0\\.026522440573938145\ \(0\)\
\-\ lymphoma\\:\\ 0\\.025761588970353223\ \(0\)\
\-\ ldh\\:\\ 0\\.02257292203023954\ \(0\)\
\-\ b\\-cell\\:\\ 0\\.02244308380801695\ \(0\)\
\-\ non\\:\\ 0\\.02235642212169943\ \(0\)\
\-\ measuring\\:\\ 0\\.021628833686384463\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.02155296826705026\ \(0\)\
\-\ pathological\\:\\ 0\\.02104167522142364\ \(0\)\
\-\ s\\:\\ 0\\.02068158368873069\ \(0\)\
\-\ sweats\\:\\ 0\\.020524365845506626\ \(0\)\
\-\ compression\\:\\ 0\\.0202452362424046\ \(0\)\
\-\ according\\:\\ 0\\.020063609339325227\ \(0\)\
\-\ fracture\\:\\ 0\\.019013285487533997\ \(0\)\
\-\ chop\\-rituximab\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ thereapy\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ ipi\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ extra\\-nodal\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ roentgenography\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ chills\\:\\ 0\\.018026260091546387\ \(0\)\
\-\ bone\\:\\ 0\\.017919280012319575\ \(0\)\
\-\ x\\:\\ 0\\.01784219199587011\ \(0\)\
\-\ showed\\:\\ 0\\.017732932075466435\ \(0\)\
\-\ mass\\:\\ 0\\.017551111916947155\ \(0\)\
\-\ night\\:\\ 0\\.017519322066896333\ \(0\)\
\-\ our\\:\\ 0\\.017138937691392967\ \(0\)\
\-\ 740\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ x18\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ 12x13\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ chop\\-r\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ decrease\\:\\ 0\\.01649891833556147\ \(0\)\
\-\ were\\:\\ 0\\.016373724360252497\ \(0\)\
\-\ 50\\-year\\-old\\:\\ 0\\.016280392690502927\ \(0\)\
\-\ large\\:\\ 0\\.015768290563975353\ \(0\)\
\-\ ca\\-125\\:\\ 0\\.015673468487018158\ \(0\)\
\-\ menopausal\\:\\ 0\\.015673468487018158\ \(0\)\
\-\ immunohistochemistry\\:\\ 0\\.015673468487018158\ \(0\)\
\-\ meets\\:\\ 0\\.015673468487018158\ \(0\)\
\-\ lymphnode\\:\\ 0\\.015202701501123201\ \(0\)\
\-\ 12\\.7\\:\\ 0\\.015202701501123201\ \(0\)\
\-\ assay\\:\\ 0\\.015202701501123201\ \(0\)\
\-\ she\\:\\ 0\\.015182190768697293\ \(0\)\
\-\ 4\\:\\ 0\\.015069442437842058\ \(0\)\
\-\ stable\\:\\ 0\\.014861660756295383\ \(0\)\
\-\ cm\\:\\ 0\\.014506051378588517\ \(0\)\
\-\ 7\\.6\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ sub\\-centimeter\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ adjunctive\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ meeting\\:\\ 0\\.014211132663052028\ \(0\)\
\-\ confirmatory\\:\\ 0\\.01396264524605544\ \(0\)\
\-\ 7\\.4\\:\\ 0\\.013740365677157071\ \(0\)\
\-\ \\)\\:\\ 0\\.01354818402746782\ \(0\)\
\-\ worrisome\\:\\ 0\\.013539289348455965\ \(0\)\
\-\ weakness\\:\\ 0\\.01339076520265141\ \(0\)\
\-\ extremity\\:\\ 0\\.013186324766423787\ \(0\)\
\-\ cycles\\:\\ 0\\.013030508637871812\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.012923821878231498\ \(0\)\
\-\ weight\\:\\ 0\\.012923821878231498\ \(0\)\
\-\ international\\:\\ 0\\.012620896793059666\ \(0\)\
\-\ raises\\:\\ 0\\.012620896793059666\ \(0\)\
\-\ retrospective\\:\\ 0\\.012620896793059666\ \(0\)\
\-\ fever\\:\\ 0\\.012199420365198168\ \(0\)\
\-\ multiloculated\\:\\ 0\\.012175097017390453\ \(0\)\
\-\ adjuvant\\:\\ 0\\.012076953524489835\ \(0\)\
\-\ prognostic\\:\\ 0\\.012076953524489835\ \(0\)\
\-\ back\\:\\ 0\\.011894794663913405\ \(0\)\
\-\ density\\:\\ 0\\.011863423446666493\ \(0\)\
\-\ study\\:\\ 0\\.011863423446666493\ \(0\)\
\-\ may\\:\\ 0\\.011862837777836227\ \(0\)\
\-\ radiation\\:\\ 0\\.011832283753427578\ \(0\)\
\-\ cycle\\:\\ 0\\.011807262867295986\ \(0\)\
\-\ fluid\\-filled\\:\\ 0\\.011644897801607951\ \(0\)\
\-\ mainly\\:\\ 0\\.01149414049362874\ \(0\)\
\-\ warranted\\:\\ 0\\.011422618232709581\ \(0\)\
\-\ diagnose\\:\\ 0\\.011422618232709581\ \(0\)\
\-\ sufficient\\:\\ 0\\.011221541904008476\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.011097405828010725\ \(0\)\
\-\ clinical\\:\\ 0\\.011094134177493688\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.010980169855110281\ \(0\)\
\-\ some\\:\\ 0\\.010949064362307\ \(0\)\
\-\ diffuse\\:\\ 0\\.010915643123946476\ \(0\)\
\-\ patient\\:\\ 0\\.010842935834384658\ \(0\)\
\-\ benefit\\:\\ 0\\.010763599909835844\ \(0\)\
\-\ primary\\:\\ 0\\.010680946256943866\ \(0\)\
\-\ \\(\\:\\ 0\\.010667789206132962\ \(0\)\
\-\ index\\:\\ 0\\.010475465869739324\ \(0\)\
\-\ evaluation\\:\\ 0\\.010473581416990748\ \(0\)\
\-\ loss\\:\\ 0\\.010466093554719154\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.010387548788725467\ \(0\)\
\-\ two\\:\\ 0\\.010326292141839685\ \(0\)\
\-\ carcinoma\\:\\ 0\\.010219104092893951\ \(0\)\
\-\ therapeutic\\:\\ 0\\.010143850714628748\ \(0\)\
\-\ low\\:\\ 0\\.010026025539520672\ \(0\)\
\-\ combined\\:\\ 0\\.009960282408743455\ \(0\)\
\-\ criteria\\:\\ 0\\.009857349572942965\ \(0\)\
\-\ remarkable\\:\\ 0\\.009791415936858354\ \(0\)\
\-\ alone\\:\\ 0\\.009759206080042345\ \(0\)\
\-\ collections\\:\\ 0\\.009696225145127408\ \(0\)\
\-\ whether\\:\\ 0\\.009696225145127408\ \(0\)\
\-\ ascending\\:\\ 0\\.00966542599023046\ \(0\)\
\-\ tomography\\:\\ 0\\.009635070004044595\ \(0\)\
\-\ due\\:\\ 0\\.009621422586298901\ \(0\)\
\-\ duration\\:\\ 0\\.009546537938434825\ \(0\)\
\-\ computed\\:\\ 0\\.00951783403114415\ \(0\)\
\-\ fact\\:\\ 0\\.009489515422848498\ \(0\)\
\-\ \\]\\:\\ 0\\.00943399367534349\ \(0\)\
\-\ \\[\\:\\ 0\\.009406771302271954\ \(0\)\
\-\ suspicion\\:\\ 0\\.009353358205258682\ \(0\)\
\-\ that\\:\\ 0\\.009341650180752047\ \(0\)\
\-\ leukemia\\:\\ 0\\.009250425369458193\ \(0\)\
\-\ thus\\:\\ 0\\.008968713570672282\ \(0\)\
\-\ six\\:\\ 0\\.008861598960179828\ \(0\)\
\-\ 48\\:\\ 0\\.008820230877081987\ \(0\)\
\-\ pancreatic\\:\\ 0\\.008820230877081987\ \(0\)\
\-\ localized\\:\\ 0\\.008779658383563238\ \(0\)\
\-\ vital\\:\\ 0\\.008624748112350542\ \(0\)\
\-\ 23\\:\\ 0\\.008569468845696484\ \(0\)\
\-\ prognosis\\:\\ 0\\.008551359681790594\ \(0\)\
\-\ or\\:\\ 0\\.008451668767626224\ \(0\)\
\-\ 3\\:\\ 0\\.008442934711841939\ \(0\)\
\-\ pole\\:\\ 0\\.008395013748976835\ \(0\)\
\-\ be\\:\\ 0\\.0083402324262274\ \(0\)\
\-\ was\\:\\ 0\\.008339894702225204\ \(0\)\
\-\ afebrile\\:\\ 0\\.008329080112892226\ \(0\)\
\-\ mri\\:\\ 0\\.008283864366728353\ \(0\)\
\-\ local\\:\\ 0\\.008280947881318026\ \(0\)\
\-\ node\\:\\ 0\\.008249459167780734\ \(0\)\
\-\ ovarian\\:\\ 0\\.008249459167780734\ \(0\)\
\-\ must\\:\\ 0\\.008218433540376314\ \(0\)\
\-\ nodes\\:\\ 0\\.00814280878980008\ \(0\)\
\-\ poor\\:\\ 0\\.008113301950190922\ \(0\)\
\-\ pe\\:\\ 0\\.008098701859801527\ \(0\)\
\-\ adenopathy\\:\\ 0\\.008027179598882368\ \(0\)\
\-\ \\,\\:\\ 0\\.007995655943548572\ \(0\)\
\-\ fall\\:\\ 0\\.007930954891599557\ \(0\)\
\-\ pathologic\\:\\ 0\\.007891022381292554\ \(0\)\
\-\ either\\:\\ 0\\.007851831694429823\ \(0\)\
\-\ resolution\\:\\ 0\\.007775569006420727\ \(0\)\
\-\ measures\\:\\ 0\\.007714057225215124\ \(0\)\
\-\ for\\:\\ 0\\.007691014226188978\ \(0\)\
\-\ stage\\:\\ 0\\.007689946052591447\ \(0\)\
\-\ but\\:\\ 0\\.0076898873461330695\ \(0\)\
\-\ collection\\:\\ 0\\.007630846820043613\ \(0\)\
\-\ features\\:\\ 0\\.0076076630192512176\ \(0\)\
\-\ best\\:\\ 0\\.007584731221283066\ \(0\)\
\-\ involved\\:\\ 0\\.007562046006565214\ \(0\)\
\-\ procedure\\:\\ 0\\.007550794221807065\ \(0\)\
\-\ condition\\:\\ 0\\.007539602128495476\ \(0\)\
\-\ after\\:\\ 0\\.007459920686114778\ \(0\)\
\-\ free\\:\\ 0\\.007420255395397597\ \(0\)\
\-\ 12\\:\\ 0\\.007378477700679919\ \(0\)\
\-\ includes\\:\\ 0\\.0072676801599975424\ \(0\)\
\-\ additional\\:\\ 0\\.007228790493987336\ \(0\)\
\-\ progressive\\:\\ 0\\.007125398976884604\ \(0\)\
\-\ also\\:\\ 0\\.007108099551350849\ \(0\)\
\-\ worsening\\:\\ 0\\.007098059009284383\ \(0\)\
\-\ colon\\:\\ 0\\.007080027235912108\ \(0\)\
\-\ subsequent\\:\\ 0\\.007018102737995383\ \(0\)\
\-\ malignancy\\:\\ 0\\.00696643391941248\ \(0\)\
\-\ second\\:\\ 0\\.0069243226481834974\ \(0\)\
\-\ incidental\\:\\ 0\\.006826558223587079\ \(0\)\
\-\ fractures\\:\\ 0\\.006826558223587079\ \(0\)\
\-\ confirmed\\:\\ 0\\.006779324057145142\ \(0\)\
\-\ ago\\:\\ 0\\.006710398356112339\ \(0\)\
\-\ appears\\:\\ 0\\.006710398356112339\ \(0\)\
\-\ a\\:\\ 0\\.006693667541242215\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.0066291037063185764\ \(0\)\
\-\ mm\\:\\ 0\\.0066291037063185764\ \(0\)\
\-\ pain\\:\\ 0\\.006605114984371738\ \(0\)\
\-\ cervical\\:\\ 0\\.006550825752303014\ \(0\)\
\-\ presence\\:\\ 0\\.0065438515157323395\ \(0\)\
\-\ identified\\:\\ 0\\.006441913589000678\ \(0\)\
\-\ kidney\\:\\ 0\\.006351019947362889\ \(0\)\
\-\ signs\\:\\ 0\\.006344674966215304\ \(0\)\
\-\ complete\\:\\ 0\\.006344674966215304\ \(0\)\
\-\ to\\:\\ 0\\.006306912993883763\ \(0\)\
\-\ given\\:\\ 0\\.006180199140329836\ \(0\)\
\-\ now\\:\\ 0\\.006162691117514023\ \(0\)\
\-\ elevated\\:\\ 0\\.00611670118430182\ \(0\)\
\-\ this\\:\\ 0\\.006083146919709703\ \(0\)\
\-\ three\\:\\ 0\\.006077266304529347\ \(0\)\
\-\ cases\\:\\ 0\\.0060059300927871985\ \(0\)\
\-\ spine\\:\\ 0\\.005936927312247569\ \(0\)\
\-\ finding\\:\\ 0\\.005810256339743631\ \(0\)\
\-\ revealed\\:\\ 0\\.005785809894232264\ \(0\)\
\-\ superior\\:\\ 0\\.005756843242730361\ \(0\)\
\-\ adjacent\\:\\ 0\\.005700076464418284\ \(0\)\
\-\ found\\:\\ 0\\.005681488638084624\ \(0\)\
\-\ post\\:\\ 0\\.005676867158380366\ \(0\)\
\-\ tenderness\\:\\ 0\\.005482937390045639\ \(0\)\
\-\ no\\:\\ 0\\.005445849055087354\ \(0\)\
\-\ only\\:\\ 0\\.005420699701445012\ \(0\)\
\-\ renal\\:\\ 0\\.0054166150832448716\ \(0\)\
\-\ and\\:\\ 0\\.005316721688293372\ \(0\)\
\-\ 5\\:\\ 0\\.005274600047350555\ \(0\)\
\-\ focal\\:\\ 0\\.00514872068383629\ \(0\)\
\-\ fluid\\:\\ 0\\.005123711191147369\ \(0\)\
\-\ weeks\\:\\ 0\\.005116619740297781\ \(0\)\
\-\ ct\\:\\ 0\\.005043475330768113\ \(0\)\
\-\ secondary\\:\\ 0\\.00504014760866837\ \(0\)\
\-\ an\\:\\ 0\\.004985927697403923\ \(0\)\
\-\ months\\:\\ 0\\.0049239267820465555\ \(0\)\
\-\ presented\\:\\ 0\\.004914256613971327\ \(0\)\
\-\ therapy\\:\\ 0\\.004819917291646863\ \(0\)\
\-\ these\\:\\ 0\\.004691655468265485\ \(0\)\
\-\ patients\\:\\ 0\\.004665769196974738\ \(0\)\
\-\ anterior\\:\\ 0\\.004643022834942483\ \(0\)\
\-\ both\\:\\ 0\\.004603797448704897\ \(0\)\
\-\ acute\\:\\ 0\\.004451222213304842\ \(0\)\
\-\ soft\\:\\ 0\\.004390140852307067\ \(0\)\
\-\ 1\\:\\ 0\\.0042897180758643605\ \(0\)\
\-\ tissue\\:\\ 0\\.004273040481967497\ \(0\)\
\-\ tumor\\:\\ 0\\.004203021733356142\ \(0\)\
\-\ woman\\:\\ 0\\.0041643522098922066\ \(0\)\
\-\ most\\:\\ 0\\.004162099455122523\ \(0\)\
\-\ diagnosis\\:\\ 0\\.004139703229494556\ \(0\)\
\-\ lower\\:\\ 0\\.004054561327771862\ \(0\)\
\-\ it\\:\\ 0\\.0040524227521793596\ \(0\)\
\-\ contrast\\:\\ 0\\.004035391744320475\ \(0\)\
\-\ of\\:\\ 0\\.003932617748455305\ \(0\)\
\-\ have\\:\\ 0\\.0039038778024579994\ \(0\)\
\-\ 2\\:\\ 0\\.0038820769968576922\ \(0\)\
\-\ findings\\:\\ 0\\.003837208725295273\ \(0\)\
\-\ right\\:\\ 0\\.0038043532029975384\ \(0\)\
\-\ treatment\\:\\ 0\\.0036489809274280315\ \(0\)\
\-\ has\\:\\ 0\\.0033854429757263246\ \(0\)\
\-\ the\\:\\ 0\\.0032083167336284467\ \(0\)\
\-\ disease\\:\\ 0\\.0029467036734508525\ \(0\)\
\-\ there\\:\\ 0\\.0026829442119514525\ \(0\)\
\-\ from\\:\\ 0\\.002671805302013106\ \(0\)\
\-\ not\\:\\ 0\\.0026051026829998635\ \(0\)\
\-\ at\\:\\ 0\\.00244253829711315\ \(0\)\
\-\ is\\:\\ 0\\.0023725349298933567\ \(0\)\
\-\ in\\:\\ 0\\.0017780473845580376\ \(0\)\
\-\ with\\:\\ 0\\.0017279097734793842\ \(0\)\
\-\ \\.\\:\\ 0\\.0016476577935477174\ \(0\)\
